RYTM — Rhythm Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $4.03bn
- $3.81bn
- $130.13m
Annual cashflow statement for Rhythm Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -134 | -69.6 | -181 | -185 | -261 |
| Depreciation | |||||
| Non-Cash Items | 17.2 | -79.4 | 25.7 | 42 | 135 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.89 | 1.9 | -19.7 | 4.81 | 10.6 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -122 | -146 | -173 | -136 | -114 |
| Capital Expenditures | -0.214 | -0.434 | -0.281 | -0.047 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 159 | -61.7 | 28.3 | -5.62 | -48.2 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 159 | -62.2 | 28 | -5.67 | -48.2 |
| Financing Cash Flow Items | — | — | — | — | 8.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.01 | 166 | 214 | 74.4 | 191 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 38.6 | -41.7 | 68.4 | -67.6 | 29.2 |